Iclaprim

Expert Opinion on Investigational Drugs

Volumn 16, Issue 9, 2007, Pages 1441-1448

  Kohlhoff, Stephan A ^a   Sharma, Roopali ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

Author keywords

Antibiotics; Complicated skin and skin structure infections; Dihydrofolate reductase inhibitors; Iclaprim

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; DIHYDROFOLATE REDUCTASE; DOXYCYCLINE; ERYTHROMYCIN; ICLAPRIM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; PENICILLIN DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFADIAZINE; SULFAMETHOXAZOLE; TELAVANCIN; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE; TRIMETHOPRIM; TROVAFLOXACIN; VANCOMYCIN; ANTIINFECTIVE AGENT; FOLIC ACID ANTAGONIST; NEW DRUG; PYRIMIDINE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PERITONITIS; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COST CONTROL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; ERYTHEMA; HOSPITAL INFECTION; HUMAN; LOW DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PRURITUS; QT PROLONGATION; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA; ANIMAL; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUGS, INVESTIGATIONAL; FOLIC ACID ANTAGONISTS; HUMANS; PYRIMIDINES;

EID: 34548553297     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.9.1441     Document Type: Article

References (38)

1. HAWSER S, LOCIURO S, ISLAM K: Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol. (2006) 71:941-948.
2. SCHNEIDER P, HAWSER S, ISLAM K: Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg. Med. Chem. Lett. (2003) 13:4217-4221.
3. SORBERA LA, CASTANER J, RABASSEDAX: Iclaprim. Drugs Future (2004) 29:220-225.
4. FISCHER RL, LUNDSBY KL, FRIMODT-MOLLER N: PK/PD evaluation of iclaprim in two experimental mouse models. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (14-17 September 2003) (Abstract A-305).
5. JOHN BA, HENDERSON SJ, HARRIS SE et al.: Metabolism and pharmacokinetics of iclaprim mesylate in the rat. 13th North-American International Society for the Study of Xenobiotics, Maui, USA (23-27 October 2005) (Poster).
6. BRANDT R, IRONS S, MCBURNEY A et al.: Pharmacokinetics of single and multiple doses of iclaprim given by intravenous infusion in healthy volunteers. 3rd International Symposium on Resistant Gram-Positive Infections, Niagara-On-The-Lake, Canada (9-11 October 2006) (Abstract P33).
7. HAWSER S, WEISS L, FISCHER M et al.: AR-100, a novel diaminopyrimidine compound: bactericidal activity and post-antibiotic effect on Gram-positive pathogens. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (27-30 September 2002) (Abstract F-2029)
8. ZHANEL GG, GOOLIA M, RUSEN J et al.: Pharmacodynamic activity of iclaprim vs. resistant Streptococcus pneumoniae using an in vitro model. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic (1-4 May 2004) (Abstract P1026).
9. ZHANEL GG, PALATNICK LP, HISNAGA TL et al.: Activity of iclaprim against penicillin, erythromycin, trimethoprim/sulfamethoxazole or ciprofloxacin-resistant Streptococcus pneumoniae from Canada. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (14-17 September 2003): E2002.
10. HAWSER S, WEISS L, FISCHER M et al.: AR-100, a novel diaminopyrrimidine compound: activity against selected Gram-positive and Gram-negative bacterial pathogens and synergy with other antibiotics. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA (27-30 September 2002) (Abstract F-2019).
11. WEISS L, GILLESSEN D, HAWSER S et al.: Iclaprim, a novel diaminopyrimidine antibiotic: synergy studies with different classes of antibiotics. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic (1-4 May 2004) (Abstract P532).
12. ANDREWS JM, HONEYBOURNE D, ASHBY JP et al.: Concentrations of iclaprim in plasma, epithelial lining fluid (Elf) alveolar macrophages (Am) and bronchial mucosa (Mb) following a single 1.6 mg/kg intravenous infusion in healthy subjects. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (16-19 December 2005) (Abstract A-9).
13. PARISI S, HALDIMANN H, MAINIER C et al.: In vitro activities of iclaprim against trimethoprim-sensitive and -resistant enzymes. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (14-17 September 2003) (Abstract E-2005).
14. GEMMELL CG, MIDDLEMAS G: AR-100, a novel diaminopyrimidine: activity against various clinical isolates of Gram-positive and Gram-negative bacteria. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, USA (2002) (Abstract F-2022).
15. GOOD CE, WINDAU A, BAJAKSOUZIAN S et al.: AR-100, a novel diaminopyrimidine compound: activity against streptococci. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA (27-30 September 2002) (Abstract F-2023).
16. BOZDOGAN B, ESEL D, WHITENER C et al.: Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. J. Antimicrob. Chemother. (2003) 52:864-868.
17. TENOVER FC, WEIGEL LM, APPELBAUM PC et al.: Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. (2004) 48:275-280.
18. THEN RL, HARTMANN PG, LOCHER HH: AR-100, a novel diaminopyrimidine compound: in vitro activity against pneumococci. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA (27-30 September 2002) (Abstract F-2021).
19. MILATOVIC D, VERHOEF J, FLUIT AC: In vitro activity of iclaprim (AR-100) against Gram-positive and Gram-negative bacteria. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (14-17 September 2003) (Abstract E-2006).
20. THEN RL, LOCHER HH, ANGEHRN P: AR-100, a novel diaminopyrimidine compound: in vitro activity against Gram-positive and Gram-negative bacterial pathogens. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA (27-30 September 2002) (Abstract F-2018).
21. JACOBS MR, WINDAU A, BAJAKSOUZIAN S et al.: AR-100, a novel diaminopyrimidine compound: activity against Haemophilus species and Moraxella catarrhalis. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA (27-30 September 2002) (Abstract F-2026).
22. HOBAN DJ, PALATNICK LP, HISANAGA TL et al.: In vitro activity of iclaprim (formerly AR-100) against lower gastrointestinal tract isolates. 71st Annual Canadian Association for Clinical Microbiology and Infectious Diseases, Montreal, Canada (2-5 November 2003) (Abstract P37).
23. WINDAU A, BAJAKSOUZIAN S, APPELBAUM PC et al.: AR-100, a novel ciaminopyrimidine compound: activity against enterobacteriaceae. 42nd Intencience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA (27-30 September 2002) (Abstract F-2025).
24. EDNIE L, JACOBS M, APPELBAUM P: AR-100, a novel diaminopyrimidine compound: anti-anaerobe activity compared to other agents. 42nd Interscience Confirence on Antimicrobial Agents and Chemotherapy, San Diego, USA (27-30 September 2002) (Abstract F-2027).
25. KOHLHOFF SA, ROBLIN PM, REZNIK T et al.: In vitro activity of a novel diaminopyrimidine comound, iclaprim, against Chlamydia trachomatis and C. pneumoniae. Antimicrob. Agents Chemother. (2004) 48:1885-1886.
26. MORISSEY I, HAWSER S, ISLAM K et al.: Activity of iclaprim and comparators against atypical bacterial respiratory pathogens. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (14-17 September 2003) (Abstract E-2003).
27. ALIOUAT EM, DEI-CAS E, GANTOIS N et al.: Anti-pneumocystis activity of iclaprim, a reliable therapeutic alternative against pneumocystis pneumonia. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic (1-4 May 2004) (Abstract P533).
28. HAWSER S, HALDIMANN A, PARISI S et al.: AR-100, a novel diaminopyrimidine compound: resistance studies in trimethoprim-sensitive and -resistant Staplylococcus aureus. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (27-30 September 2002) (Abstract F-2028).
29. KRIEVENS D, LEIGHTON A, BRANDT R et al.: Efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections: results of a Phase II study. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2005) (Abstract L-1579).
30. ENTENZA JM, GIDDEY M, VOUILLAMOZ J et al.: In vitro plasma fibrin clot models versus in vivo models of experimental endocarditis: case study for diaminopyrimidine antibiotics iclaprim and trimethoprim/ sulfamethoxazole. 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic (1-4 May 2004) (Abstract P534).
31. CANDIANI GP, ROMANO G, JABES D et al.: AR-100, a novel diaminopyrimidine compound: in vivo efficacy in a murine model of staphylococcal septicemia. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA (27-30 September 2002) (Abstract F-2030).
32. KRESSE H, BELSEY MJ, ROVINI H: The antibacterial drugs market. Nat. Rev. (2007) 6:19-20.
33. ROSS DB: The FDA and the case of Ketek. N. Engl. J. Med. (2007) 356:1601-1604.
34. MANDELL LA, WUNDERINK RG, ANZUETO A et al.: Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. (2007) 44:S27-S72.
35. PETERSON DS, WALLIKER D, WELLEMS TE: Evidence that a point mutation in dihydrofolate reductasethymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. USA (1988) 85:9114-9118.
36. THOMSON CJ: Trimethoprim and brodimoprim resistance of Gram-positive and Gram-negative bacteria. J. Chemother. (1993) 5:458-464.
37. BAJAKSOUZIAN S, WINDAU A, APPELBAUM PC et al.: AR-100, a novel diaminopyrimidine compund: activity against staphylococci and enterococci. 42nd Interscience Confirence on Antimicrobial Agents and Chemotherapy, San Diego, USA (27-30 September 2002) (Abstract F-2024).
38. FISCHER M, WEISS L, SCHEIDEGGER D et al.: Iclaprim, a novel diaminopyrimidine antibiotic: in vitro and intracellular activitiy against Listeria monocytogenes. 42nd Interscience Conftrence on Antimicrobial Agents and Chemotherapy, San Diego, USA (27-30 September 2002) (Abstract E-2004).